SQ53 Wipe for Infections

The inheritance pattern of infections and the familial clustering of infections suggest an important role of genetic and environmental factors to promote infectious diseases within families.

Nearly 11 million individuals in the U.S. are infected by at least one community-acquired bacterial or viral disease each year. Most infections are subclinical. Many are self-limiting and resolve without specific intervention beyond a basic treatment. Most hospitalized infections are related to invasive microbial pathogens.

Current therapies are generally only effective in controlling and minimizing symptoms. Patients with persistent infections and chronic symptoms may not benefit from current therapies and may have prolonged morbidity and shortened life.

Signs include abdominal pains, body aches and joint pains. Signs of infections may also include fevers and lethargy. A sudden worsening of one’s symptoms may suggest an infection.\n

The development of immunity appears to be related to a number of factors including genetics and infections at an earlier stage are important risk factors for autoimmune disease development later in life.\n

The main treatments for infections are antibiotics and supportive treatments. Patients must be aware that the efficacy of a particular treatment depends on the type of infection. Patients with infections require medical or complementary treatment in addition to their antibiotic treatment, as well as medical or complementary treatment to promote good healing.

Findings from a recent study identify associations between SNPs and specific clinical outcomes that may be predictive of treatment efficacy or adverse events. For example, the SNP rs3837999 in the ITGAM gene was shown to be an independent predictor of infection-related failure-free survival in patients with acute myeloid leukemia treated with intensive treatment containing cytarabine and daunorubicin. Findings from a recent study suggest potential clinical utility of this SNP in risk stratification and/or treatment of acute myeloid leukemia.

We found no evidence of persistent adverse effects in people receiving Ssq53 after 6 months of use. We have therefore concluded that Ssq53 can be used safely without interruption in the 6 months following the start of use, using a single application of 2 % Ssq53 ointment.

Oral Sq53 as prescribed in this study improved the quality of life of patients with Sq, and resulted in a low rate of symptomatic recurrence or readmission within 9 months of treatment.

Most patients do recover from an infection of moderate to severe severity, although some of the infections continue to linger and are difficult to manage. Current research has been done to find a way to prevent, stop, or treat infections when they occur.

This article gives an overview of recent evidence on the seriousness of infections. In particular, the use of the new, high resolution, multi-detector endovaginal ultrasound (MDEUS) technology and the identification of intra-patient phenotyping in clinical conditions, allow to detect infections in women who previously may not have been diagnosed. The study demonstrated the need to increase awareness of the potential of this diagnostic tool.